Waist-to-Height Ratio and OSA Risk: NHANES and Clinical Data Analysis

A 17.1 KB document by Yajing Li, last updated in May 2026, presents a comparative analysis of waist-to-height ratio (WHtR) as a predictor for obstructive sleep apnea (OSA). It uses data from the US National Health and Nutrition Examination Survey (NHANES) and a retrospective clinical dataset of 200 patients from Tianjin Chest Hospital, China. The study employs multivariate logistic regression, restricted cubic spline analysis, and ROC curves to assess the association.

Use Cases

• Evaluating waist-to-height ratio as a predictive biomarker for obstructive sleep apnea based on the described statistical analyses.
• Comparing the performance of WHtR against BMI for OSA risk prediction using ROC curve analysis results.
• Investigating non-linear relationships between anthropometric measures and disease risk via restricted cubic spline analysis.
• Conducting subgroup analysis of clinical prediction models across sex and age strata as described.

Strengths

• Includes data from two distinct sources: a nationally representative survey (NHANES) and a clinical cohort of 200 patients.
• Reports specific statistical results, including odds ratios (e.g., OR 11.998 for clinical data) and AUC values (e.g., 0.883 for clinical data).
• Identifies precise risk thresholds for WHtR (0.589 in NHANES, 0.523 in clinical data).

Limitations

• The dataset is a 17.1 KB DOCX file; the underlying raw data tables are not directly accessible.
• Row count and column-level documentation are unknown, limiting suitability assessment for direct analysis.
• The clinical data is from a single hospital in China, which may limit generalizability.

Provenance

Source

National Health and Nutrition Examination Survey (NHANES) and Sleep Center of Tianjin Chest Hospital, China.

Collection Method

Retrospective analysis of cross-sectional survey data and clinical patient records.

Freshness

Last updated 2026-05-29 05:33:37; freshness should be verified.

Geography

United States (NHANES) and Tianjin, China (clinical data).